KROS
Keros Therapeutics, Inc.
Latest Form 4:Sale$46KbyCho Esther (Chief Legal Officer) · filed Aug 20, 2026
Keros Therapeutics, Inc. (KROS) has 32 SEC Form 4 filings (40 transaction rows) in the rolling window, disclosed by 12 distinct insiders. Most recent filing: Aug 20, 2026.
The most active filer is Director BIENAIME JEAN JACQUES with 6 filings. Insiders have net sold $115K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Jasbir S. Seehra
- Employees:163
- HQ:Lexington, MA, US
- IPO:2020-04-08
Insider Buying
$76K
reported purchases (SEC code P)
Insider Selling
$181.2M
reported sales (SEC code S)
Unique Insiders
12
in the rolling window
Market Cap
$218.7M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Cho EstherFirst in 6 months | Chief Legal Officer | Sale | 4,485 | $46K | Aug 20 | SEC ↗ |
Lerner Lorena RaquelFirst in 6 months | Chief Scientific Officer | Sale | 3,568 | $37K | Aug 20 | SEC ↗ |
Tanini AnnitaFirst filing | Corp. Controller & VP, Finance | Sale | 1,224 | $13K | Aug 20 | SEC ↗ |
| Director | Sale | 551 | $6K | Aug 20 | SEC ↗ | |
| Director | Purchase | 1,000 | $10K | Aug 19 | SEC ↗ | |
| Director | Purchase | 1,000 | $11K | Jul 17 | SEC ↗ | |
| Director | Purchase | 1,000 | $10K | Jun 17 | SEC ↗ | |
Newton Charles W.First filing | Director | Sale | 550 | $6K | Jun 15 | SEC ↗ |
Knowles JuliusFirst filing | Director | Sale | 2,625 | $28K | Jun 8 | SEC ↗ |
Farzan NimaFirst filing | Director | Sale | 2,625 | $28K | Jun 8 | SEC ↗ |
Seth AlpnaFirst filing | Director | Sale | 2,625 | $28K | Jun 5 | SEC ↗ |
| Director | Purchase | 1,000 | $11K | May 19 | SEC ↗ | |
| Director | Purchase | 1,000 | $12K | Apr 17 | SEC ↗ | |
BIENAIME JEAN JACQUESFirst filing | Director | Purchase | 2,000 | $22K | Mar 11 | SEC ↗ |
Lerner Lorena RaquelFirst filing | Chief Science Officer | Sale | 3,873 | $63K | Feb 20 | SEC ↗ |
Regnante KeithFirst filing | CHIEF FINANCIAL OFFICER | Sale | 4,739 | $77K | Feb 20 | SEC ↗ |
Cho EstherFirst filing | SVP, General Counsel | Sale | 4,745 | $78K | Feb 20 | SEC ↗ |
Seehra JasbirFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 7,015 | $113K | Feb 20 | SEC ↗ |
| 10% Owner | Sale | 4,787,331 | $85.0M | Oct 17 | SEC ↗ | |
ADAR1 Capital Management, LLCFirst filing | 10% Owner | Sale | 5,389,264 | $95.7M | Oct 15 | SEC ↗ |
Related companies
Keros Therapeutics, Inc. is in the Healthcare sector.